阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌(GO30140):开放标签、多中心、1b期研究
GO30140是一项开放标签、多中心、多臂1b期研究,评估阿替利珠单抗单药或联合贝伐珠单抗在不可切除肝细胞癌初治患者中的疗效与安全性。A组104例接受联合治疗,确认客观缓解率36%(95%CI 26-46);联合治疗常见3-4级治疗相关不良事件为高血压和蛋白尿。
要点
- 阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌初治患者中确认客观缓解率达36%。
- 联合治疗常见3-4级不良事件为高血压(13%)和蛋白尿(7%),需关注治疗相关死亡(3%)。
核心结论
- 在不可切除且未接受过系统治疗的肝细胞癌患者中,阿替利珠单抗联合贝伐珠单抗较阿替利珠单抗单药显著延长无进展生存期。
- 联合方案可能成为此类患者有前景的治疗选择,正在3期试验中与索拉非尼标准治疗进行比较。
研究设计与样本
- GO30140为开放标签、多中心、多臂1b期研究,在7个国家26个学术中心和社区肿瘤实践点入组患者。
- 本文描述肝细胞癌A组和F组:A组104例接受阿替利珠单抗(1200 mg)联合贝伐珠单抗(15 mg/kg)静脉每3周;F组119例按1:1随机分配至联合组(60例)或阿替利珠单抗单药组(59例)。
- 主要终点:A组为确认客观缓解率(独立评审机构按RECIST 1.1评估),F组为意向治疗人群的无进展生存期。
临床怎么用
- 对于不可切除、未接受过系统治疗的肝细胞癌患者,可考虑阿替利珠单抗联合贝伐珠单抗治疗。
- 治疗期间需监测高血压和蛋白尿等不良反应,并警惕治疗相关严重不良事件及死亡。
局限性
- 本研究为1b期研究,样本量有限,F组随访时间较短。
- F组主要终点采用80%CI进行统计学推断,非传统95%CI。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual blockade of PD-L1 and VEGF has enhanced anticancer immunity through multiple mechanisms and augmented antitumour activity in multiple malignancies. We aimed to assess the efficacy and safety of atezolizumab (anti-PD-L1) alone and combined with bevacizumab (anti-VEGF) in patients with unresectable hepatocellular carcinoma. METHODS: GO30140 is an open-label, multicentre, multiarm, phase 1b study that enrolled patients at 26 academic centres and community oncology practices in seven countries worldwide. The study included five cohorts, and the two hepatocellular carcinoma cohorts, groups A and F, are described here. Inclusion criteria for these two groups included age 18 years and older; histologically, cytologically, or clinically (per American Association for the Study of Liver Diseases criteria) confirmed unresectable hepatocellular carcinoma that was not amenable to curative treatment; no previous systemic treatment; and Eastern Cooperative Oncology Group performance status of 0 or 1. In group A, all patients received atezolizumab (1200 mg) and bevacizumab (15 mg/kg) intravenously every 3 weeks. In group F, patients were randomly assigned (1:1) to receive intravenous atezolizumab (1200 mg) plus intravenous bevacizumab (15 mg/kg) every 3 weeks or atezolizumab alone by interactive voice-web response system using permuted block randomisation (block size of two) and stratification factors of geographical region; macrovascular invasion, extrahepatic spread, or both; and baseline α-fetoprotein concentration. Primary endpoints were confirmed objective response rate in all patients who received the combination treatment for group A and progression-free survival in the intention-to-treat population in group F, both assessed by an independent review facility according to Response Evaluation Criteria in Solid Tumors version 1.1. In both groups, safety was assessed in all patients who received at least one dose of any study treatment. This study is registered with ClinicalTrials.gov, NCT02715531, and is closed to enrolment. FINDINGS: In group A, 104 patients were enrolled between July 20, 2016, and July 31, 2018, and received atezolizumab plus bevacizumab. With a median follow-up of 12·4 months (IQR 8·0-16·2), 37 (36%; 95% CI 26-46) of 104 patients had a confirmed objective response. The most common grade 3-4 treatment-related adverse events were hypertension (13 [13%]) and proteinuria (seven [7%]). Treatment-related serious adverse events occurred in 25 (24%) patients and treatment-related deaths in three (3%) patients (abnormal hepatic function, hepatic cirrhosis, and pneumonitis). In group F, 119 patients were enrolled and randomly assigned (60 to atezolizumab plus bevacizumab; 59 to atezolizumab monotherapy) between May 18, 2018, and March 7, 2019. With a median follow-up of 6·6 months (IQR 5·5-8·5) for the atezolizumab plus bevacizumab group and 6·7 months (4·2-8·2) for the atezolizumab monotherapy group, median progression-free survival was 5·6 months (95% CI 3·6-7·4) versus 3·4 months (1·9-5·2; hazard ratio 0·55; 80% CI 0·40-0·74; p=0·011). The most common grade 3-4 treatment-related adverse events in group F were hypertension (in three [5%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group) and proteinuria (in two [3%] patients in the atezolizumab plus bevacizumab group; none in the atezolizumab monotherapy group). Treatment-related serious adverse events occurred in seven (12%) patients in the atezolizumab plus bevacizumab group and two (3%) patients in the atezolizumab monotherapy group. There were no treatment-related deaths. INTERPRETATION: Our study shows longer progression-free survival with a combination of atezolizumab plus bevacizumab than with atezolizumab alone in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy. Therefore, atezolizumab plus bevacizumab might become a promising treatment option for these patients. This combination is being compared with standard-of-care sorafenib in a phase 3 trial. FUNDING: F Hoffmann-La Roche/Genentech.
引用
- Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020. PMID: 32502443. doi:10.1016/S1470-2045(20)30156-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。